Biogen and its investors both want US appeals court to clarify class certification
In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...
Buy Rating Justified by Biogen’s Strategic Positioning and Strong Financial Outlook
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BIIB stock, giving a Buy rating on September 24. Salim Syed has ...
The Best Performing S&P 500 Stocks Over the Past 30 Years Might Surprise You
A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
However, the drugmaker's prospects look so strong that not only should it soon join the $1 trillion club, but it could even ...
Japan Today10d
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...
Investopedia3d
The Best Performing S&P 500 Stocks Over the Past 30 Years Might Surprise You
Biogen's accelerated approval of Aduhelm and subsequent pushback from the medical community, payers (insurers and customers), and even the FDA cast a shadow on Biogen's Alzheimer's strategy and ...